Translating the MAM model of psychosis to humans

Trends in Neurosciences

Volumn 38, Issue 3, 2015, Pages 129-138

  Modinos, Gemma ^a   Allen, Paul ^a   Grace, Anthony A ^b   McGuire, Philip ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Animal research; Neurobiology; Neuroimaging; Prodrome; Psychosis; Schizophrenia

Indexed keywords

DOPAMINE; GLUTAMIC ACID; METHYLAZOXYMETHANOL ACETATE;

BRAIN SIZE; DOPAMINERGIC SYSTEM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GRAY MATTER; HUMAN; NEUROBIOLOGY; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RODENT MODEL; SCHIZOPHRENIA; ANIMAL; BRAIN; DISEASE MODEL; PATHOLOGY;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; METHYLAZOXYMETHANOL ACETATE; PSYCHOTIC DISORDERS;

EID: 84924497225     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2014.12.005     Document Type: Review

References (135)

1. Howes O.D., et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch. Gen. Psychiatry 2012, 69:776-786.
2. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 2003, 160:13-23.
3. Howes O.D., et al. Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging. Curr. Pharm. Des. 2009, 15:2550-2559.
4. Honea R., et al. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am. J. Psychiatry 2005, 162:2233-2245.
5. Arnold S.E. The medial temporal lobe in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1997, 9:460-470.
6. Tamminga C.A., et al. The hippocampal formation in schizophrenia. Am. J. Psychiatry 2010, 167:1178-1193.
7. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr. Bull. 2009, 35:549-562.
8. Lodge D.J., Grace A.A. Aberrant hippocampal activity underlies the dopamine dysregulation in an animal model of schizophrenia. J. Neurosci. 2007, 27:11424-11430.
9. Lodge D.J., Grace A.A. Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia. Trends Pharmacol. Sci. 2011, 32:507-513.
10. Flagstad P., et al. Disruption of neurogenesis on gestational day 17 in the rat causes behavioral changes relevant to positive and negative schizophrenia symptoms and alters amphetamine-induced dopamine release in nucleus accumbens. Neuropsychopharmacology 2004, 29:2052-2064.
11. Grace A.A., Moore H. Regulation of information flow in the nucleus accumbens: a model for the pathophysiology of schizophrenia. Origins and Development of Schizophrenia: Advances in Experimental Psychopathology 1998, 123-157. American Psychological Association Press. M.F. Lenzenweger, R.H. Dworkin (Eds.).
12. Moore H., et al. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol. Psychiatry 2006, 60:253-264.
13. Lisman J., et al. A neoHebbian framework for episodic memory; role of dopamine-dependent late LTP. Trends Neurosci. 2011, 34:536-547.
14. Lisman J.E., Grace A.A. The hippocampal-VTA loop: controlling the entry of information into long-term memory. Neuron 2005, 46:703-713.
15. Logothetis N.K. The neural basis of the blood-oxygen-level-dependent functional magnetic resonance imaging signal. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2002, 357:1003-1037.
16. Port J.D., Agarwal N. MR spectroscopy in schizophrenia. J. Magn. Reson. Imaging 2011, 34:1251-1261.
17. Waschkies C.F., et al. Neuropharmacological and neurobiological relevance of in vivo (1)H-MRS of GABA and glutamate for preclinical drug discovery in mental disorders. Neuropsychopharmacology 2014, 39:2331-2339.
18. Mackay A.V., et al. Increased brain dopamine and dopamine receptors in schizophrenia. Arch. Gen. Psychiatry 1982, 39:991-997.
19. Zakzanis K.K., Hansen K.T. Dopamine D2 densities and the schizophrenic brain. Schizophr. Res. 1998, 32:201-206.
20. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int. J. Neuropsychopharmacol. 2004, 7(Suppl 1):S1-S5.
21. Hietala J., et al. Measurement of striatal D2 dopamine receptor density and affinity with [11C]-raclopride in vivo: a test-retest analysis. J. Cereb. Blood Flow Metab. 1999, 19:210-217.
22. Lindstrom L.H., et al. Increased dopamine synthesis rate in medial prefrontal cortex and striatum in schizophrenia indicated by L-(beta-11C) DOPA and PET. Biol. Psychiatry 1999, 46:681-688.
23. Laruelle M., et al. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9235-9240.
24. Davis K.L., et al. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148:1474-1486.
25. Shenton M.E., et al. Amygdala-hippocampal shape differences in schizophrenia: the application of 3D shape models to volumetric MR data. Psychiatry Res. 2002, 115:15-35.
26. Lawrie S.M., Abukmeil S.S. Brain abnormality in schizophrenia. A systematic and quantitative review of volumetric magnetic resonance imaging studies. Br. J. Psychiatry 1998, 172:110-120.
27. Steen R.G., et al. Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br. J. Psychiatry 2006, 188:510-518.
28. Wright I.C., et al. Meta-analysis of regional brain volumes in schizophrenia. Am. J. Psychiatry 2000, 157:16-25.
29. Andreasen N.C., et al. Hypofrontality in schizophrenia: distributed dysfunctional circuits in neuroleptic-naive patients. Lancet 1997, 349:1730-1734.
30. Malaspina D., et al. Resting neural activity distinguishes subgroups of schizophrenia patients. Biol. Psychiatry 2004, 56:931-937.
31. Scheef L., et al. Resting-state perfusion in nonmedicated schizophrenic patients: a continuous arterial spin-labeling 3.0-T MR study. Radiology 2010, 256:253-260.
32. Pinkham A., et al. Resting quantitative cerebral blood flow in schizophrenia measured by pulsed arterial spin labeling perfusion MRI. Psychiatry Res. 2011, 194:64-72.
33. Horn H., et al. Structural and metabolic changes in language areas linked to formal thought disorder. Br. J. Psychiatry 2009, 194:130-138.
34. Holt D.J., et al. Increased medial temporal lobe activation during the passive viewing of emotional and neutral facial expressions in schizophrenia. Schizophr. Res. 2006, 82:153-162.
35. Holt D.J., et al. Sustained activation of the hippocampus in response to fearful faces in schizophrenia. Biol. Psychiatry 2005, 57:1011-1019.
36. Hall J., et al. Overactivation of fear systems to neutral faces in schizophrenia. Biol. Psychiatry 2008, 64:70-73.
37. Tamminga C.A., et al. Hippocampal novelty activations in schizophrenia: disease and medication effects. Schizophr. Res. 2012, 138:157-163.
38. Heinz A., Schlagenhauf F. Dopaminergic dysfunction in schizophrenia: salience attribution revisited. Schizophr. Bull. 2010, 36:472-485.
39. Marsman A., et al. Glutamate in schizophrenia: a focused review and meta-analysis of (1)H-MRS studies. Schizophr. Bull. 2013, 39:120-129.
40. Kraguljac N.V., et al. Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia. JAMA Psychiatry 2013, 70:1294-1302.
41. Bustillo J.R., et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol. Psychiatry 2011, 69:19-27.
42. Theberge J., et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am. J. Psychiatry 2002, 159:1944-1946.
43. Theberge J., et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br. J. Psychiatry 2007, 191:325-334.
44. Choe B.Y., et al. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest. Radiol. 1996, 31:345-352.
45. Ongur D., et al. Elevated gamma-aminobutyric acid levels in chronic schizophrenia. Biol. Psychiatry 2010, 68:667-670.
46. Goto N., et al. Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study. Schizophr. Res. 2009, 112:192-193.
47. Yoon J.H., et al. GABA concentration is reduced in visual cortex in schizophrenia and 47 with orientation-specific surround suppression. J. Neurosci. 2010, 30:3777-3781.
48. Stan A.D., et al. Magnetic resonance spectroscopy and tissue protein concentrations together suggest lower glutamate signaling in dentate gyrus in schizophrenia. Mol. Psychiatry 2014, Published June 10, 2014. http://dx.doi.org/10.1038/mp.2014.54.
49. Brugger S., et al. Proton magnetic resonance spectroscopy and illness stage in schizophrenia--a systematic review and meta-analysis. Biol. Psychiatry 2011, 69:495-503.
50. Kegeles L.S., et al. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. Psychiatry Res. 2000, 98:163-175.
51. Fusar-Poli P., et al. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci. Biobehav. Rev. 2013, 37:1680-1691.
52. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychol. Med. 2009, 39:1763-1777.
53. Ho B.C., et al. Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia. Arch. Gen. Psychiatry 2011, 68:128-137.
54. Abbott C.C., et al. Antipsychotic drug effects in schizophrenia: a review of longitudinal FMRI investigations and neural interpretations. Curr. Med. Chem. 2013, 20:428-437.
55. Handley R., et al. Acute effects of single-dose aripiprazole and haloperidol on resting cerebral blood flow (rCBF) in the human brain. Hum. Brain Mapp. 2013, 34:272-282.
56. de la Fuente-Sandoval C., et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry 2013, 70:1057-1066.
57. Fusar-Poli P., et al. Predicting psychosis meta-analysis of transition outcomes in individuals at high clinical risk. Arch. Gen. Psychiatry 2012, 69:220-229.
58. Howes O.D., et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch. Gen. Psychiatry 2009, 66:13-20.
59. Egerton A., et al. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol. Psychiatry 2013, 74:106-112.
60. Howes O.D., et al. Dopamine synthesis capacity before onset of psychosis: a prospective [(18)F]-DOPA PET imaging study. Am. J. Psychiatry 2011, 168:1311-1317.
61. Allen P., et al. Transition to psychosis associated with prefrontal and subcortical dysfunction in ultra high-risk individuals. Schizophr. Bull. 2012, 38:1268-1276.
62. Howes O., et al. Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol. Psychiatry 2011, 16:885-886.
63. Phillips L.J., et al. Non-reduction in hippocampal volume is associated with higher risk of psychosis. Schizophr. Res. 2002, 58:145-158.
64. Borgwardt S.J., et al. Regional gray matter volume abnormalities in the at risk mental state. Biol. Psychiatry 2007, 61:1148-1156.
65. Witthaus H., et al. Hippocampal subdivision and amygdalar volumes in patients in an at-risk mental state for schizophrenia. J. Psychiatry Neurosci. 2010, 35:33-40.
66. Wood S.J., et al. Hippocampal pathology in individuals at ultra-high risk for psychosis: a multi-modal magnetic resonance study. Neuroimage 2010, 52:62-68.
67. Wood S.J., et al. Hippocampal and anterior cingulate morphology in subjects at ultra-high-risk for psychosis: the role of family history of psychotic illness. Schizophr. Res. 2005, 75:295-301.
68. Hurlemann R., et al. Interrelated neuropsychological and anatomical evidence of hippocampal pathology in the at-risk mental state. Psychol. Med. 2008, 38:843-851.
69. Velakoulis D., et al. Hippocampal and amygdala volumes according to psychosis stage and diagnosis - a magnetic resonance imaging study of chronic schizophrenia, first-episode psychosis, and ultra-high-risk individuals. Arch. Gen. Psychiatry 2006, 63:139-149.
70. Fusar-Poli P., et al. Neuroanatomy of vulnerability to psychosis: a voxel-based meta-analysis. Neurosci. Biobehav. Rev. 2011, 35:1175-1185.
71. Smieskova R., et al. Neuroimaging predictors of transition to psychosis: a systematic review and meta-analysis. Neurosci. Biobehav. Rev. 2010, 34:1207-1222.
72. Pantelis C., et al. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 2003, 361:281-288.
73. Mechelli A., et al. Neuroanatomical abnormalities that predate the onset of psychosis: a multicenter study. Arch. Gen. Psychiatry 2011, 68:489-495.
74. Allen P., et al. Altered prefrontal and hippocampal function during verbal encoding and recognition in people with prodromal symptoms of psychosis. Schizophr. Bull. 2011, 37:746-756.
75. Fusar-Poli P., et al. Altered brain function directly related to structural abnormalities in people at ultra high risk of psychosis: longitudinal VBM-fMRI study. J. Psychiatr. Res. 2011, 45:190-198.
76. Seiferth N.Y., et al. Increased neural response related to neutral faces in individuals at risk for psychosis. Neuroimage 2008, 40:289-297.
77. Modinos G., et al. Overactivation of emotional brain systems predicts severity of positive symptoms and global functioning in prodromal and first-episode psychosis. Presented at the 9th International Conference on Early Psychosis 2014, International Early Psychosis Association (IEPA). http://www.iepaconference.org/.
78. Schobel S.A., et al. Differential targeting of the CA1 subfield of the hippocampal formation by schizophrenia and related psychotic disorders. Arch. Gen. Psychiatry 2009, 66:938-946.
79. Stone J.M., et al. Glutamate dysfunction in people with prodromal symptoms of psychosis: relationship to gray matter volume. Biol. Psychiatry 2009, 66:533-539.
80. Egerton A., et al. Relationship between brain glutamate levels and clinical outcome in individuals at ultra high risk of psychosis. Neuropsychopharmacology 2014, 39:2891-2899.
81. de la Fuente-Sandoval C., et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology 2011, 36:1781-1791.
82. de la Fuente-Sandoval C., et al. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int. J. Neuropsychopharmacol. 2013, 16:471-475.
83. Natsubori T., et al. Reduced frontal glutamate + glutamine and n-acetylaspartate levels in patients with chronic schizophrenia but not in those at clinical high risk for psychosis or with first-episode schizophrenia. Schizophr. Bull. 2014, 40:1128-1139.
84. Marin O. Interneuron dysfunction in psychiatric disorders. Nat. Rev. Neurosci. 2012, 13:107-120.
85. Day M., et al. Glutamate-receptor-mediated encoding and retrieval of paired-associate learning. Nature 2003, 424:205-209.
86. Valli I., et al. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol. Psychiatry 2011, 69:97-99.
87. Fusar-Poli P., et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch. Gen. Psychiatry 2011, 68:881-890.
88. Allen P., et al. Functional outcome in people at high risk for psychosis predicted by thalamic glutamate levels and prefronto-striatal activation. Schizophr. Bull. 2014, pii: sbu115 [Epub ahead of print].
89. Stone J.M., et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol. Psychiatry 2010, 68:599-602.
90. Allen P., et al. Abnormal relationship between medial temporal lobe and subcortical dopamine function in people with an ultra high risk for psychosis. Schizophr. Bull. 2012, 38:1040-1049.
91. Roiser J.P., et al. Neural and behavioral correlates of aberrant salience in individuals at risk for psychosis. Schizophr. Bull. 2013, 39:1328-1336.
92. Kapur S., et al. From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr. Res. 2005, 79:59-68.
93. Fusar-Poli P., et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis: a multimodal imaging study. Arch. Gen. Psychiatry 2010, 67:683-691.
94. Fusar-Poli P., et al. Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis. Mol. Psychiatry 2011, 16:67-75.
95. Godsil B.P., et al. The hippocampal-prefrontal pathway: the weak link in psychiatric disorders?. Eur. Neuropsychopharmacol. 2013, 23:1165-1181.
96. Schobel S.A., et al. Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. Neuron 2013, 78:81-93.
97. Choi D.W. Calcium and excitotoxic neuronal injury. Ann. N. Y. Acad. Sci. 1994, 747:162-171.
98. Lodge D.J., Grace A.A. Divergent activation of ventromedial and ventrolateral dopamine systems in animal models of amphetamine sensitization and schizophrenia. Int. J. Neuropsychopharmacol. 2012, 15:69-76.
99. Alexander G.E., et al. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu. Rev. Neurosci. 1986, 9:357-381.
100. Volk D.W., et al. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 2000, 57:237-245.
101. Yaakub S.N., et al. Preserved working memory and altered brain activation in persons at risk for psychosis. Am. J. Psychiatry 2013, 170:1297-1307.
102. Brune M., et al. An fMRI study of 'theory of mind' in at-risk states of psychosis: comparison with manifest schizophrenia and healthy controls. Neuroimage 2011, 55:329-337.
103. Mondelli V., et al. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72:1677-1684.
104. Mondelli V., Howes O. Inflammation: its role in schizophrenia and the potential anti-inflammatory effects of antipsychotics. Psychopharmacology 2014, 231:317-318.
105. Gill K.M., et al. Prior antipsychotic drug treatment prevents response to novel antipsychotic agent in the methylazoxymethanol acetate model of schizophrenia. Schizophr. Bull. 2014, 40:341-350.
106. Nyffeler M., et al. Maternal immune activation during pregnancy increases limbic GABAA receptor immunoreactivity in the adult offspring: implications for schizophrenia. Neuroscience 2006, 143:51-62.
107. Jaaro-Peled H., et al. Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models. Schizophr. Bull. 2010, 36:301-313.
108. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
109. Krystal J.H., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994, 51:199-214.
110. Lahti A.C., et al. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
111. Lodge D.J., Grace A.A. Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia. Behav. Brain Res. 2009, 204:306-312.
112. Lodge D.J., et al. A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia. J. Neurosci. 2009, 29:2344-2354.
113. Gastambide F., et al. Selective remediation of reversal learning deficits in the neurodevelopmental MAM model of schizophrenia by a novel mGlu5 positive allosteric modulator. Neuropsychopharmacology 2012, 37:1057-1066.
114. Akbarian S., et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52:258-266.
115. Hammad H., Wagner J.J. Dopamine-mediated disinhibition in the CA1 region of rat hippocampus via D3 receptor activation. J. Pharmacol. Exp. Ther. 2006, 316:113-120.
116. Gonzalez-Burgos G., Lewis D.A. NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophr. Bull. 2012, 38:950-957.
117. Cohen M.X., et al. Connectivity-based segregation of the human striatum predicts personality characteristics. Nat. Neurosci. 2009, 12:32-34.
118. Bunzeck N., Duzel E. Absolute coding of stimulus novelty in the human substantia nigra/VTA. Neuron 2006, 51:369-379.
119. Winton-Brown T.T., et al. Dopaminergic basis of salience dysregulation in psychosis. Trends Neurosci. 2014, 37:85-94.
120. Carr D.B., Sesack S.R. Hippocampal afferents to the rat prefrontal cortex: synaptic targets and relation to dopamine terminals. J. Comp. Neurol. 1996, 369:1-15.
121. Seamans J.K., Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog. Neurobiol. 2004, 74:1-58.
122. Giusti-Rodriguez P., Sullivan P.F. The genomics of schizophrenia: update and implications. J. Clin. Invest. 2013, 123:4557-4563.
123. Callaghan B.L., Richardson R. Maternal separation results in early emergence of adult-like fear and extinction learning in infant rats. Behav. Neurosci. 2011, 125:20-28.
124. Gao J., et al. Glutamate and GABA imbalance promotes neuronal apoptosis in hippocampus after stress. Med. Sci. Monit. 2014, 20:499-512.
125. Caldji C., et al. The effects of early rearing environment on the development of GABAA and central benzodiazepine receptor levels and novelty-induced fearfulness in the rat. Neuropsychopharmacology 2000, 22:219-229.
126. Zimmerman E.C., et al. Abnormal stress responsivity in a rodent developmental disruption model of schizophrenia. Neuropsychopharmacology 2013, 38:2131-2139.
127. Du Y., Grace A.A. Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia. Neuropsychopharmacology 2013, 38:1881-1888.
128. Day F., et al. Blunted cortisol awakening response in people at ultra high risk of developing psychosis. Schizophr. Res. 2014, 158:25-31.
129. Thompson K.N., et al. HPA axis functioning associated with transition to psychosis: combined DEX/CRH test. J. Psychiatr. Res. 2007, 41:446-450.
130. Walker E.F., et al. Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol. Psychiatry 2013, 74:410-417.
131. Mondelli V., et al. Higher cortisol levels are associated with smaller left hippocampal volume in first-episode psychosis. Schizophr. Res. 2010, 119:75-78.
132. Watabe-Uchida M., et al. Whole-brain mapping of direct inputs to midbrain dopamine neurons. Neuron 2012, 74:858-873.
133. Belujon P., et al. Disruption of prefrontal cortical-hippocampal balance in a developmental model of schizophrenia: reversal by sulpiride. Int. J. Neuropsychopharmacol. 2013, 16:507-512.
134. Belujon P., et al. Role of the prefrontal cortex in altered hippocampal-accumbens synaptic plasticity in a developmental animal model of schizophrenia. Cereb. Cortex 2014, 24:968-977.
135. Modinos G., et al. Effect of dorsomedial prefrontal GABA levels on brain perfusion in people at ultra high risk for psychosis. Presented at the 9th International Conference on Early Psychosis 2014, International Early Psychosis Association (IEPA). http://www.iepaconference.org/.